Geriatric Psychiatry Update: ChEIs for Psychotic Symptoms
According to this recent meta-analysis published in JAMA Neurology on June 26, 2023: Cholinesterase Inhibitors treatment improves psychotic symptoms in patients with Alzheimer’s disease &…
According to this recent meta-analysis published in JAMA Neurology on June 26, 2023: Cholinesterase Inhibitors treatment improves psychotic symptoms in patients with Alzheimer’s disease &…
PSYCHIATRY EDUCATION FORUM ACADEMY’S APATHY IN ALZHEIMER’S DISEASE BASICS & BEYOND Alzheimer’s disease, a progressive neurodegenerative disorder, not only affects memory and cognitive functions but…
On July 06, 2023: FDA announced the approval of Leqembi (Lecanemab) for adult patients with early Alzheimer’s Disease or mild cognitive impairment. Psychiatry Education Forum…
On May 11, 2023: FDA announced the approval of Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the…
On March 14, 2022: FDA has approved the first and only once-weekly transdermal patch for Alzheimer’s dementia: Adlarity (Donepezil). Psychiatry Education Forum Academy has summarized…
Psychiatry Education Forum Academy published its next discussion series today: It is important to have knowledge of these six neuro-cognitive domains for the evaluation &…
Alzheimer’s disease is the most common type/cause of dementia. As we know that FDA recently approved Aducanumab (Aduhelm) for the treatment of Alzheimer’s Disease (read…
June 07, 2021 Today FDA has approved Aducanumab (Aduhelm) for the treatment of Alzheimer’s Disease. This is the first novel treatment to target the underlying…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.